Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) announced it will report its first quarter financial results and corporate update on May 3, 2023, at 5:00 p.m. Eastern Time. A conference call will provide insights into the company's current financial standing and future plans. Participants must register in advance for the call to receive a unique access PIN. Additionally, a listen-only webcast will be available for those unable to attend the call. Corcept is known for its proprietary cortisol modulators aimed at treating serious health disorders like Cushing's syndrome, cancer, and PTSD. Its drug Korlym® was the first approved treatment for Cushing’s syndrome in the U.S.
- Upcoming conference call on financial results and corporate update may provide valuable insights for investors.
- Corcept's leading drug, Korlym®, holds a significant position in the market as the first FDA-approved treatment for Cushing's syndrome.
- None.
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
Additionally, a listen-only webcast will be available by clicking here.
A replay of the call will be available on the Investors / Events tab of www.corcept.com.
About Corcept Therapeutics
Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective cortisol modulators as potential treatments for patients with serious disorders – Cushing’s syndrome, ovarian, prostate and adrenal cancer, ALS, post-traumatic stress disorder and liver disease. Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.
CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics report its financial results?
What time is the conference call for Corcept's financial results?
How can I listen to the Corcept Therapeutics conference call?
What is Korlym® used to treat?
What is the significance of the upcoming call for investors?
